BioCentury
ARTICLE | Company News

Daiichi Sankyo, Kissei Pharmaceutical sales and marketing update

April 29, 2013 7:00 AM UTC

Daiichi launched silodosin to treat dysuria associated with benign prostatic hyperplasia (BPH) in China. Daiichi has rights from Kissei to develop and market the selective adrenergic receptor alpha 1...